marked.bio

Company

Quanta Therapeutics

2 active trials that select patients by a biomarker on marked.bio, across 1 biomarker.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

cetuximab 2

Trials

2 of 2 trials shown

  1. QTX3046 in Patients With KRAS G12D Mutations

    Active, not recruiting Phase 1 Quanta Therapeutics Started 2024Primary completion 2027-07 NCT06428500

    QTX3046cetuximab

    Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutations identified through molecular testing (NGS- or PCR-based) with a Clinical Labora…

    KRAS G12DAdvanced Solid Tumor

  2. QTX3034 in Patients With KRAS G12D Mutation

    Recruiting Phase 1 Quanta Therapeutics Started 2024Primary completion 2027-04 NCT06227377

    QTX3034cetuximab

    Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laborat…

    KRAS G12DSolid Tumors